ERBB2 and breast cancer: The association of pathologic complete response (pCR) following neoadjuvant chemotherapy with improved survival outcomes in breast cancer, particularly for human epidermal growth factor receptor 2 (HER2)-positive and triple negative subtypes, has been previously reported [1,2].